105558-26-7
105558-26-7 結(jié)構(gòu)式
基本信息
人參皂苷 S-RH3
人參皂苷RH3對(duì)照品,
人參皂苷RH3(標(biāo)準(zhǔn)品)
20(S)-人參皂苷RH3, 來(lái)源于人參根莖
ginsenoside Rh3 USP/EP/BP
20(S)-Ginsenoside Rh3, 98%, from panax ginseng C. A. Mey.
[(20Z)-12β-Hydroxy-5α-dammara-20(22),24-dien-3β-yl]β-D-glucopyranoside
b-D-Glucopyranoside, (3b,12b,20Z)-12-hydroxydammara-20(22),24-dien-3-yl
β-D-Glucopyranoside, (3β,12β,20Z)-12-hydroxydammara-20(22),24-dien-3-yl
(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[[(8R,10R,12S,13R,14S,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2Z)-6-methylhepta-2,5-dien-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxane-3,4,5-triol
物理化學(xué)性質(zhì)
應(yīng)用領(lǐng)域
藥理藥效:具有抗炎作用，可顯著抑制LPS誘導(dǎo)活化的小神經(jīng)膠質(zhì)細(xì)胞表達(dá)iNOs和前炎癥細(xì)胞因子。
常見(jiàn)問(wèn)題列表
人參皂苷Rh3是Rg5通過(guò)生物代謝轉(zhuǎn)化而來(lái)的一種分子量更小的人參皂苷，它的功效比Rg5更強(qiáng)。
Nrf2
Ginsenoside Rh3 inhibits UV-induced oxidative damages in retinal cells via activating nuclear-factor-E2-related factor 2 (Nrf2) signaling. Ginsenoside Rh3 treatment in retinal cells induces Nrf2 activation. The potential activity of Ginsenoside Rh3 is tested on Nrf2 signaling in the retinal pigment epithelium cells (RPEs). The qRT-PCR assay results demonstrate that treatment with Ginsenoside Rh3 dose-dependently increases mRNA transcription and expression of key Nrf2-regulated genes, including HO1 , NQO1 and GCLC . Consequently, protein expressions of these Nrf2-dependent genes (HO1, NQO1 and GCLC) are also significantly increased in Ginsenoside Rh3 (3-10?μM)-treated RPEs. Notably, although Nrf2 mRNA level is unchanged after Ginsenoside Rh3 treatment, its protein level is significantly increased by Rh3. EZ-Cytox assay is used to assess the effect of ginsenoside-Rh3 on SP 1-keratinocytes viability. Ginsenoside Rh3 (0.01, 0.1, 1 and 10 μM) shows no cytotoxic effect at all concentrations.
The potential effect of Ginsenoside Rh3 is examined on mouse retina, using the light-induced retinal damage model. Ginsenoside Rh3 intravitreal injection (5?mg/kg body weight, 30?min pre-treatment) significantly attenuates light-induced decrease of both a- and b-wave amplitude. The electroretinography (ERG)'s a-wave decreases to 46.03±1.62% % of control level after light exposure, which is back to 71.84±7.51% with Ginsenoside Rh3 administration. The b-wave is 40.19±3.34% of control level by light exposure, and Rh3 intravitreal injection brings back to 80.01±2.37% of control level.